Cargando…
Spontaneous reduction of prolactinoma post cabergoline withdrawal
Prolactinomas are common pituitary tumors usually highly responsive to dopamine agonists. Around 70-90% of the prolactinomas exhibit decrease in tumor size, though variably with these agents. Uncommonly, there may be little or no shrinkage in pituitary tumor. In the absence of medical therapy, pitui...
Autores principales: | Venkatesh, Sampath Kumar, Kothari, Deepak, Manchanda, Smita, Taneja, Anil, Kulshreshtha, Bindu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475917/ https://www.ncbi.nlm.nih.gov/pubmed/23087877 http://dx.doi.org/10.4103/2230-8210.100656 |
Ejemplares similares
-
Cabergoline Treatment in Invasive Giant Prolactinoma
por: Alsubaie, Sadeem, et al.
Publicado: (2014) -
Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline
por: Ghadirian, Hesam, et al.
Publicado: (2018) -
Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma
por: Hayes, Annabelle G, et al.
Publicado: (2022) -
Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?
por: Vilar, Lucio, et al.
Publicado: (2015) -
Cabergoline treatment in prolactinoma: Amelioration in obstructive and central sleep apneas
por: Binar, M, et al.
Publicado: (2019)